2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-173041
    Arginase inhibitor 9 98%
    Arginase inhibitor 9 (Compound 12a) is an arginase inhibitor with IC50 values of 9 μM and 55 μM for bovine and human arginase I, respectively. Arginase inhibitor 9 exhibits antioxidant activity and can scavenge free radicals. Additionally, Arginase inhibitor 9 can effectively regulate the levels of collagen and procollagen, exerting an anti-fibrotic effect.
    Arginase inhibitor 9
  • HY-173046
    NLRP3-IN-71 3026419-44-0 98%
    NLRP3-IN-71 (Compound 19) is a BBB-permeable, orally active and selective NLRP3 inhibitor that can inhibit IL-1β secretion. NLRP3-IN-71 can be used for the research of neurodegenerative diseases.
    NLRP3-IN-71
  • HY-173052
    SLW131 681511-84-2 98%
    SLW131 is a CCR7 antagonist with a Ki value of 9.85 nM. SLW131 inhibits CCL19-induced Go protein activation with an IC50 of 29.4 μM, and suppresses β-arrestin2 recruitment with an IC50 of 6.0 μM. SLW131 serves as a probe for investigating the biological functions of CCR7 in cells. SLW131 is applicable to research related to rheumatoid arthritis.
    SLW131
  • HY-173055
    Ferroleuton 98%
    Ferroleuton is a competitive, selective inhibitor for 5-lipoxygenase with an IC50 of 0.21 μM. Ferroleuton exhibits antioxidant activity in DPPH (scavenges 86% DPPH-H at 50 μM), ABTS (EC50=19.42 μM) and FRAP (EC50=3.32 μM) assays.
    Ferroleuton
  • HY-173056
    Ruthenoleuton 98%
    Ruthenoleuton is a 5-lipoxygenase (5-LOX) inhibitor with an IC50 of 3.49 μM and a Ki of 0.80 μM. Ruthenoleuton has antioxidant activity and can be used in the research of inflammatory diseases.
    Ruthenoleuton
  • HY-173070
    TLR7 agonist 29 2275612-76-3 98%
    TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC50 of 5.2 nM for human TLR7 (EC50 for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC.
    TLR7 agonist 29
  • HY-173076
    HDAC11-IN-1 98%
    HDAC11-IN-1 (Compound 14-NC6OH) is a selective macrocyclic inhibitor of HDAC11 with a Ki of 40 nM. HDAC11-IN-1 exhibits good cell permeability and can inhibit the expression of YAP1 and SOX2.
    HDAC11-IN-1
  • HY-173114
    Anti-inflammatory agent 96 98%
    Anti-inflammatory agent 96 (Compound 5), a tetrasubstituted α-aminophosphonate derivatives with a methylphosphoserine fragment, is an anti-inflammatory agent. Anti-inflammatory agent 96 can reduce TPA-induced ear edema and CFA-induced paw edema.
    Anti-inflammatory agent 96
  • HY-173115
    15-LOX-IN-2 98%
    15-LOX-IN-2 (Compound 2a) is an orally active COX-2/15-LOX inhibitor and a partial agonist of PPARγ. 15-LOX-IN-2 has anti-inflammatory activity and inhibits the levels of 20-HETE, IL-1β and TNF-α in RAW 264.7 cells treated with LPS (HY-D1056). In addition, 15-LOX-IN-2 has significant glucose uptake capacity in the absence of insulin. 15-LOX-IN-2 can be used for the research of metabolic diseases.
    15-LOX-IN-2
  • HY-173129
    Anti-inflammatory agent 97 98%
    Anti-inflammatory agent 97 (Compound 1l), an anti-inflammation agent, can also inhibit oxidative stress. Anti-inflammatory agent 97 can inhibit the colonic shortening and suppress inflammatory symptoms of the colonic tissue in the DSS (HY-116282C)-induced ulcerative colitis mice model. Anti-inflammatory agent 97 can regulate the inflammation-related TLR4/NF-κB signaling pathway and the oxidative stress-related Nrf2/HO-1 signaling pathway.
    Anti-inflammatory agent 97
  • HY-173130
    α-Glucosidase-IN-86 98%
    α-Glucosidase-IN-86 (Compound A4) is an orally active α-glucosidase inhibitor with an IC50 of 2.72 μM. α-Glucosidase-IN-86 has high safety in mice. α-Glucosidase-IN-86 can reduce fasting blood glucose levels, improve glucose tolerance, regulate blood lipids, and has antioxidant effects in diabetic mice. α-Glucosidase-IN-86 can be used for the research of diabetes.
    α-Glucosidase-IN-86
  • HY-173144
    AChE-IN-85 98%
    AChE-IN-85 (Compound 7k) is an AChE inhibitor with an IC50 of 0.083 μM. AChE-IN-85 can inhibit the release of NO, the production of TNF-α and IL-1β, the levels of LDH and ROS, as well as the aggregation of Aβ42. AChE-IN-85 has anti-inflammatory and neuroprotective effects and can be used in the research of diseases such as Alzheimer's disease.
    AChE-IN-85
  • HY-173152
    AChE/BChE-IN-26 98%
    AChE/BChE-IN-26 (Compound 20aa) is a cholinesterase inhibitor with IC50 values of 0.75 μM and 4.11 μM against eeAChE and eqBChE, respectively. AChE/BChE-IN-26 has antioxidant activity and can be used in the research of diseases such as Alzheimer's disease.
    AChE/BChE-IN-26
  • HY-173153
    BRAFV600E/JNK-IN-1 98%
    BRAFV600E/JNK-IN-1 (Compound 14c) is an inhibitor of JNK1, JNK2, JNK3 and BRAFV600E, with IC50 values of 0.51 μM, 0.53 μM, 1.02 μM and 0.009 μM, respectively. BRAFV600E/JNK-IN-1 can inhibit the phosphorylation of MEK1/2 and ERK1/2. In addition, BRAFV600E/JNK-IN-1 can inhibit tumor cell proliferation, NO release and PGE2 production, and has anti-tumor and anti-inflammatory activities.
    BRAFV600E/JNK-IN-1
  • HY-173180
    5-LOX-IN-8 98%
    5-LOX-IN-8 is a 5-LOX inhibitor with anti-inflammatory activity. 5-LOX-IN-8 suppresses IL-6, IL-1β, TNF-α and IFN-γ in macrophages and reduces IL-8 secretion in SW480 cells. 5-LOX-IN-8 reduces disease activity in a DSS colitis model. 5-LOX-IN-8 can be used for research of inflammatory bowel disease (IBD).
    5-LOX-IN-8
  • HY-173184
    HDAC6-IN-53 3081880-03-4 98%
    HDAC6-IN-53 (Compound W28) is an inhibitor targeting histone deacetylase 6 (HDAC6) with an IC50 of 19.65 nM. HDAC6-IN-53 exerts the activity of inhibiting the phenotype of idiopathic pulmonary fibrosis (IPF) by suppressing the collagen expression induced by TGF-β1, and it has demonstrated a good therapeutic effect in a mouse model of pulmonary fibrosis induced by Bleomycin (HY-17565A). HDAC6-IN-53 can be used in the research of idiopathic pulmonary fibrosis and other related pulmonary fibrosis diseases.
    HDAC6-IN-53
  • HY-173185
    RIP1-IN-1 98%
    RIP1-IN-1 is an orally active RIP1 inhibitor with strong RIP1 binding affinity (Kd: 110 nM). RIP1-IN-1 exhibits strong anti-necroptosis activity. RIP1-IN-1 effectively inhibits the formation of necrosomes by blocking the phosphorylation of RIP1, RIP3 and MLKL signaling pathways. RIP1-IN-1 inhibits necroptosis and can be used in the study of acute liver injury.
    RIP1-IN-1
  • HY-173187
    Keap1-Nrf2-IN-27 98%
    Keap1-Nrf2-IN-27 (compound 1C) is a inhibitor of Keap1-Nrf2 protein-protein interaction (PPI) with KD2 value of 0.119 μM. Keap1-Nrf2-IN-27 suppresses the expression of pro-inflammatory cytokine TNF-α and IL-6 in the LPS-induced RAW264.7 cell model.
    Keap1-Nrf2-IN-27
  • HY-173209
    NLRP3-IN-73 98%
    NLRP3-IN-73 (W16) is an orally active inhibitor of the assembly of NLRP3 inflammasome via targeting NLRP3, with an IC50 value of 0.18 μM for the NLRP3/IL-1β pathway.
    NLRP3-IN-73
  • HY-173235
    Galectin-3-IN-6 2604662-64-6 98%
    Galectin-3-IN-6 is a human and murine galectin-3 (Gal-3) inhibitor, with an IC50 of 12 nM against human galectin-3, an IC50 of 12.6 nM against mutant murine galectin-3 (V160A), and a Kd of 13 nM for human galectin-3, as well as oral bioavailability. Galectin-3-IN-6 reduces the levels of liver fibrosis markers type I collagen and α-smooth muscle actin in mouse models of acute liver injury and fibrosis. Galectin-3-IN-6 can be used for the research of acute liver injury and fibrosis.
    Galectin-3-IN-6
Cat. No. Product Name / Synonyms Application Reactivity